NCT05292781 (CHOICES3) is a NA clinical trial of CHOICES in Sickle Cell Disease, sponsored by University of Florida.

Who is sponsoring NCT05292781?

NCT05292781 is sponsored by University of Florida.

What drugs are being tested in NCT05292781?

Interventions in NCT05292781: CHOICES, eBook.

What condition does NCT05292781 study?

NCT05292781 studies Sickle Cell Disease, Sickle Cell Trait.

Is NCT05292781 still recruiting?

NCT05292781 is currently active, enrolled. Last updated 15 January 2026.

Last reviewed 2026-01-15 · How we verify

NCT05292781: CHOICES3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CHOICES3: Sickle Cell Disease Parenting CHOICES

Active, enrolled NA Last updated 15 January 2026

What this trial tests

NA trial testing CHOICES in Sickle Cell Disease in 506 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 December 2022

Primary endpoint
30 June 2027

30 June 2027

Quick facts

Lead sponsor	University of Florida
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	506
Start date	1 December 2022
Primary completion	30 June 2027
Estimated completion	30 June 2027
Sites	1 location across United States

Drugs / interventions tested

CHOICES
eBook

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sickle Cell Trait — all drugs for Sickle Cell Trait →

Sponsor

University of Florida

Who can join

Adults 18 to 45, any sex, with Sickle Cell Disease or Sickle Cell Trait. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will use web-based data collection (SCKnowIQ) and intervention delivery strategies enhanced by nudges and tailored boosters in a sample of 430 adult men and women, aged 18-45 yr with SCD (Sickle Cell Disease) or SCT (Sickle Cell Trait), at-risk, and planning within 2 years to have a child free of SCD.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Go the Distance: Reproductive Health Care for People with Sickle Cell Disease.
Pecker LH, Kuo KHM. · · 2022 · cited 14× · PMID 36400542 · DOI 10.1016/j.hoc.2022.07.010
CHOICES for sickle cell reproductive health: A protocol of a randomized preconception intervention model for a single gene disorder.
Wilkie DJ, Telisnor G, Powell-Roach K, Rangel AP, et al · · 2023 · cited 2× · PMID 38060589 · DOI 10.1371/journal.pone.0294907
Methods to modernize a multimedia, web-based reproductive health education intervention for individuals with sickle cell disease or trait using virtual human narration and user-centered design.
Gomes de Siqueira A, Gehling GM, Subramanian A, Le A, et al · · 2025 · PMID 41270235 · DOI 10.1177/14604582251397311

Verify or expand the search:

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05292781 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 15 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05292781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing